TABLE 2.

Activities of ciprofloxacin and garenoxacin against clinical isolates of S. aureus

Test compound	Ciprofloxacin phenotype of isolates	No. of isolates	No. of spa types	MIC (μg/ml)			MPC (μg/ml)			MPC/MIC ratio
				90%	Mode	Range	90%	Mode	Range
Ciprofloxacin	Susceptible	20	15	0.6	0.4	0.2-0.6	8	3-4	2-12	13
Garenoxacin	Susceptible	20	15	0.03	0.015	0.005-0.03	0.4	0.3-0.4	0.07-0.8	13
	Resistant	22	10	3.2	0.8-1.2	0.04-4.8	>19.6	9.6-12.8	3.2->28.8	>6